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Abstract: We describe an original pathway to produce new 5-substituted 3-methyl-6-nitro-
benzoxazolones by the reaction of aromatic carbonyl and α-carbonyl ester derivatives with 
a benzoxazolinonic anion formed exclusively via the TDAE strategy. 
Keywords: TDAE; benzoxazolone; benzoxazolinonic anion; benzylic alcohols; oxiranes 
 
1. Introduction 
Many benzoxazolinone derivatives have been described in therapeutics as possessing a wide variety 
of pharmacological activities [1–10]. Indeed, the clinical applications of this template are very broad, 
and range from analgesic anti-inflammatory compounds to antipsychotic and neuroprotective 
anticonvulsant compounds [11]. Several potentially useful drugs and pharmacological tools based on 
these pharmacophores have been developed in recent years [12–16]. 
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Tetrakis(dimethylamino)ethylene (TDAE) is a reducing agent which reacts with halogenated 
derivatives to generate an anion under mild conditions via two sequential transfers of one electron [17–19]. 
Through this strategy, we have developed many reactions between nitrobenzylic substrates and a series 
of electrophiles such as aldehydes, ketones, α-ketoesters, α-ketolactams and ketomalonates leading to 
corresponding alcohol adducts [20–23]. This reactivity was recently extended using original heterocyclic 
carbaldehydes as electrophiles. The reactions led to the expected products, while at the same time bringing 
to light a new and original reactivity and enabling us to define some limitations of this strategy [24]. 
Moreover, we reported the reactions of dihalo- and trihalomethyl heterocyclic derivatives with aromatic 
aldehydes in the presence of TDAE, providing a mixture of cis/trans isomers of oxiranes and α-haloketone 
derivatives, respectively [25,26]. In the same context, the expected alcohols and oxiranes were obtained 
in good yields in the quinonic series [27]. 
In continuation of our research program centered on the design and synthesis of novel bioactive 
molecules [28–32], we report herein the preparation of 5-(bromomethyl)-3-methyl-6-nitrobenzoxazolone (2) 
and 5-(dibromomethyl)-3-methyl-6-nitrobenzoxazolone (3) and the study of their reactivity with various 
aromatic carbonyl and α-carbonyl ester derivatives using the TDAE methodology. 
2. Results and Discussion 
2.1. Synthesis of Mono and Dibromide Substrates 
We prepared 5-(bromomethyl)-3-methyl-6-nitrobenzoxazolone (2) and 5-(dibromomethyl)-3-
methyl-6-nitrobenzoxazolone (3) [33] in four and five steps, respectively. The condensation of  
2-amino-4-methylphenol with urea was inspired by a previously described method [34,35]. After 
methylation using dimethyl sulfate, the nitration of the obtained 3,5-dimethylbenzoxazolone by action 
of a mixture of nitric and sulfuric acids afforded 3,5-dimethyl-6-nitrobenzoxazolone (1) in 88% yield.  
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i) DMF, 145-150°C, 3 h30.  ii) DMS, r.t., 3 h. iii) HNO3 (1 eq.), H2SO4, 0 °C, 2 h. iv) NBS (2 eq.), hv, benzoyl peroxide, CCl4, 80 °C, 8.5 h
 v) NBS (6 eq.), hv, benzoyl peroxide, CCl4, 80 °C, 10 h.
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Scheme 1. Synthesis of 5-(bromomethyl)-3-methyl-6-nitrobenzoxazolone (2) and  
5-(dibromomethyl)-3-methyl-6-nitrobenzoxazolone (3). 
The bromination of 1 with 2 equivalents of N-bromosuccinimide in refluxing CCl4 for 8.5 h gave  
5-(bromomethyl)-3-methyl-6-nitrobenzoxazolone (2) in 61% yield, accompanied by 5-(dibromomethyl)-
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3-methyl-6-nitrobenzoxazolone (3) in 38% yield. However, the preparation of this latter compound was 
optimized (76%) using 6 equivalents of N-bromosuccinimide in refluxing CCl4 for 10 h (Scheme 1). 
2.2. TDAE Reactivity of 5-(Bromomethyl)-3-methyl-6-nitrobenzoxazolone (2) 
The reaction of 5-(bromomethyl)-3-methyl-6-nitrobenzoxazolone (2) with 3 equivalents of various 
aromatic carbonyl and α-carbonyl ester derivatives 4a–j in the presence of TDAE at −20 °C for 1 h, 
followed by 2 h at room temperature (r.t.) led to the corresponding alcohol derivatives 5a–j in moderate 
to good yields (31%–72%) as shown in Table 1 and Scheme 2. 
Table 1. Reaction of bromide 2 with aromatic carbonyl and α-carbonyl ester derivatives 
using TDAE a. 
Entry a Aromatic Carbonyl R1 R2 Product Number Yield (%) b 
1 4-Nitrobenzaldehyde 4-NO2-C6H4 H 5a 52 
2 4-Bromobenzaldehyde 4-Br-C6H4 H 5b 49 
3 4-Cyanobenzaldehyde 4-CN-C6H4 H 5c 31 
4 2-Nitrobenzaldehyde 2-NO2-C6H4 H 5d 44 
5 2-Bromobenzaldehyde 2-Br-C6H4 H 5e 49 
6 3-Bromobenzaldehyde 3-Br-C6H4 H 5f 43 
7 Ethyl glyoxylate CO2C2H5 H 5g 72 
8 Diethyl ketomalonate CO2C2H5 CO2C2H5 5h 62 
Notes: a All the reactions were performed using 3 equivalents of aromatic carbonyl 4a–h, 1 equivalent of 
bromide 2 and 1 equivalent of TDAE in anhydrous DMF stirred at −20 °C for 1 h and then warmed to rt for 2 h; 
b % Yield relative to bromide 2. 
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Scheme 2. TDAE reactivity of 5-(bromomethyl)-3-methyl-6-nitrobenzoxazolone (2) with 
aromatic carbonyl and some α-keto-ester derivatives 4a–h. 
The reaction of substrate 2 with the aromatic aldehydes 4a–f under TDAE-initiated conditions 
furnished the expected alcohols 5a–f in moderate to good yields. The best yield (52%) was obtained 
with p-nitrobenzaldehyde (4a). Unexpectedly, o,p-bromobenzaldehyde (4e,4b) gave the same yield 
(49%), while o-nitrobenzaldehyde (4d) and m-bromobenzaldehyde (4f) gave approximately the same 
yield (44% and 43%, respectively). Notably, with p-nitrobenzaldehyde (4a) we observed 23% of the 
ester 6. According to a recent mechanistic study [36], the formation of the unexpected ester derivative 6 
may be explained by an electron transfer in a primary step between 4-nitrobenzaldehyde (4a) as acceptor 
and TDAE as donor. 
p-Cyanobenzaldehyde (4c) produced a moderate yield (31%). The formation of these alcohol 
derivatives may be explained by nucleophilic addition of benzazolinonic carbanions formed by the 
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action of TDAE with 5-(bromomethyl)-3-methyl-6-nitrobenzoxazolone (2) on the carbonyl group of the 
corresponding aldehyde. In summary, the difference in yields does not appear to be totally explained by 
electronic effects: the halogen groups furnished approximately the same yields in either position. With 
nitrobenzaldehydes, steric hindrance could explain the difference between o- and p-nitrobenzaldehyde 
yields (44% versus 52%). 
It is important to note that in the reactions of substrate 2 with the electrophiles 4b–f, we observed the 
unavoidable formation of the reduction product 1 [37]. Extending the reaction times to 8 h at ambient 
temperature increases its percentage, but decreases the yield of alcohol. On the other hand, after 4 h of 
reaction, the percentage of reduction product decreases at the same time as that of the alcohol: in this 
case we also observed traces of the dimerization of substrate 2. 
Moreover, after the reaction with aromatic aldehydes, we investigated the reaction of 2 with  
α-keto-ester derivatives such as ethyl glyoxylate (4g), diethyl ketomalonate (4h), acenaphtenedione (4i) 
and 1-methylisatin (4j) in the presence of TDAE. The reactions with these electrophiles furnished the 
corresponding hydroxyl derivatives 5i–j in good yields (59%–63%), as shown in Table 1 and Scheme 3. 
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Scheme 3. TDAE reactivity of the 5-(bromomethyl)-3-methyl-6-nitrobenzoxazolone (2) and 
α-diketone and α-ketolactam derivatives 4i–j. 
2.3. TDAE Reactivity of 5-(Dibromomethyl)-3-methyl-6-nitrobenzoxazolone (3) 
The optimized protocol of the dibromomethyl derivative 3, was defined with 3 equivalents of 
aromatic carbonyls 4a–h, 1 equivalent of 5-(dibromomethyl)-3-methyl-6-nitrobenzoxazolone (3) and 
1.5 equivalents of TDAE in anhydrous DMF, for 1 h at −20 °C followed by 2 h at r.t. The reactions led 
to a mixture of cis/trans isomers of the corresponding oxiranes 7a–h in moderate to good yields as 
reported in Table 2 (Scheme 4). The formation of these oxiranes may be explained by nucleophilic 
addition of a α-bromocarbanion, formed by the action of TDAE with 5-(dibromomethyl)-3-methyl-6-
nitrobenzoxazolone (3), on the carbonyl group of aldehydes 4a–h followed by an intramolecular 
nucleophilic substitution [26]. 
In the case of the nitroaromatic aldehydes, steric hindrance could explain the yield difference between 
o- and p-nitrobenzaldehyde (46% and 63%). However, this effect disappears in the o-bromo-substituted 
aldehyde which gave 64% of the corresponding oxirane, the p- and m- substituted aldehydes with 55 and 
48% yields respectively. p-Cyanobenzaldehyde gave the expected oxirane in good yield (72%). 
Under the same experimental conditions, we studied the reaction of derivative 3 with α-keto-ester 
derivatives 4g–h as reported in Table 2 (Scheme 4). Only the trans isomers of the oxiranes 7g and 7h 
were obtained in 26% and 37% yields, respectively, with ethyl glyoxylate (4g) and diethyl ketomalonate 
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(4h). Otherwise, acenaphtenedione (4i) and methyl isatin (4j) furnished mixtures of like/unlike original 
stereoisomers 7i and 7j, respectively, in good yields (Scheme 5). The diastereoisomers were separable, and 
their configuration was identified by NMR-analysis from the γ-left effect, as previously described [26,38]. 
Table 2. Reaction of dibromide 3 with aromatic carbonyl and α-carbonyl ester derivatives 
using TDAE a. 
Entry a Aromatic Carbonyl R1 R2 Oxirane Cis/Trans Isomers % b Yield (%) c 
1 4-Nitrobenzaldehyde 4-NO2-C6H4 H 7a 15/85 63 
2 4-Bromobenzaldehyde 4-Br-C6H4 H 7b 7/93 55 
3 4-Cyanobenzaldehyde 4-CN-C6H4 H 7c 15/85 72 
4 2-Nitrobenzaldehyde 2-NO2-C6H4 H 7d 32/68 46 
5 2-Bromobenzaldehyde 2-Br-C6H4 H 7e 19/81 64 
6 3-Bromobenzaldehyde 3-Br-C6H4 H 7f 7/93 48 
7 Ethyl glyoxylate CO2C2H5 H 7g 0/100 26 
8 Diethyl ketomalonate CO2C2H5 CO2C2H5 7h 0/100 37 
Notes: a All the reactions were performed using 3 equivalents of aromatic carbonyl 4a–h, 1 equivalent of 
dibromide 3 and 1.5 equivalent of TDAE in anhydrous DMF stirred at −20 °C for 1 h and then warmed to r.t 
for 2 h; b % isomers determined on 1H-NMR measurements from the crude product; c % yield relative to 
dibromide 3. 
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Scheme 4. TDAE reactivity of 5-(dibromomethyl)-3-methyl-6-nitrobenzoxazolone (3) with 
aromatic carbonyl and some α-keto-ester derivatives 4a–h. 
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Scheme 5. TDAE reactivity of 5-(dibromomethyl)-3-methyl-6-nitrobenzoxazolone (3) and  
α-keto-ester derivatives 4i–j. 
The relative cis/trans percentages of oxirane isomers reported in Table 2 showed that the stereoselectivity 
of these reactions is not only sensitive to steric hindrance, but it also depends on the nature of the 
electrophile substituents. The reactions with bromo-substituted aldehydes in either position were more 
Molecules 2015, 20 1267 
 
 
selective than with nitro-substituted aldehydes. The same percentages of cis/trans isomers were 
previously reported with p-nitro- and cyanobenzaldehyde. However, the reactions with ethyl glyoxylate 
and diethyl ketomalonate were the most selective. Moreover, stereoselectivity was recorded in the 
mixtures of like/unlike original stereoisomers with methyl isatin and acenaphtenedione. 
3. Experimental Section 
3.1. General Information  
Melting points were determined on a Buchi capillary melting point apparatus and are uncorrected. 
Elemental analyses were performed by the Centre de Microanalyses of the University of Aix-Marseille. 
Both 1H- (200 MHz) and 13C-NMR (50 MHz) spectra were determined on a Bruker AC 200 spectrometer. 
The 1H chemical shifts are reported as parts per million downfield from tetramethylsilane (Me4Si), and 
the 13C chemical shifts were referenced to the solvent peaks: CDCl3 (76.9 ppm) or Me2SO-d6 (39.6 ppm). 
Absorptions are reported using the following notation: s, singlet; d, doublet; t, triplet; q, quartet; m, a 
more complex multiplet or overlapping multiplets. The following adsorbents were used for column 
chromatography: silica gel 60 (Merck, Darmstadt, Germany, particle size 0.063–0.200 mm, 70–230 mesh 
ASTM). TLC was performed on 5 cm × 10 cm aluminium plates coated with silica gel 60 F-254 (Merck) 
in an appropriate solvent. 3,5-Dimethyl-6-nitrobenzoxazolone (1) was synthesized in three steps: 
condensation of 2-amino-4-methylphenol with urea [34], methylation using dimethyl sulfate and 
nitration by action of a mixture of nitric and sulfuric acids. 
3.2. Synthesis of Substrates 1–3 
3,5-Dimethyl-6-nitrobenzo[d]oxazol-2(3H)-one (1): yellow solid; mp 159 °C (EtOH); 1H-NMR 
(CDCl3): δ 2.70 (s, 3H, CH3), 3.45 (s, 3H, NCH3), 6.87 (s, 1H, CH), 7.95 (s, 1H, CH). 13C-NMR (CDCl3): 
δ 21.6 (CH3), 28.5 (NCH3), 107.3 (CH), 110.7 (CH), 132.2 (C), 135.7 (C), 140.2 (C), 143.5 (CNO2), 
154.3 (CO). Anal. Calcld. for C9H8N2O4 (208.17): C, 51.93; H, 3.87; N; 13.46. Found: C, 52.34; H, 3.95; 
N, 13.40.  
5-(Bromomethyl)-3-methyl-6-nitrobenzo[d]oxazol-2(3H)-one (2) and 5-(dibromomethyl)-3-methyl-
6-nitrobenzo[d]oxazol-2(3H)-one (3) were prepared according to a previously described method [27]. 
5-(Bromomethyl)-3-methyl-6-nitrobenzo[d]oxazol-2(3H)-one (2): yellow solid (EtOH); mp 120 °C;  
1H-NMR (CDCl3): δ 3.49 (s, 3H, CH3), 4.91 (s, 2H, CH2Br), 7.14 (s, 1H, CH), 7.99 (s, 1H, CH).  
13C-NMR (CDCl3): δ 28.7 (NCH3), 29.3 (CH2Br), 108.0 (CH), 110.6 (CH), 131.1 (C), 136.1 (C), 141.7 
(C), 142.6 (CNO2), 153.9 (CO). Anal. Calcld for C9H7BrN2O4 (287.07): C, 37.66; H, 2.46; N; 9.76. 
Found: C, 38.48; H, 2.58; N, 9.88. 
5-(Dibromomethyl)-3-methyl-6-nitrobenzo[d]oxazol-2(3H)-one (3): yellow solid (EtOH); mp 134 °C;  
1H-NMR (CDCl3): δ 3.55 (s, 3H, NCH3), 7.55 (s, 1H, CHBr2), 7.75 (s, 1H, CH), 7.78 (s, 1H, CH).  
13C-NMR (CDCl3): δ 29.0 (NCH3), 34.4 (CHBr2), 106.2 (CH), 110.7 (CH), 134.3 (C), 136.5 (C), 139.0 
(C), 142.0 (CNO2), 153.6 (CO). Anal. Calcld for C9H7BrN2O4 (365.96): C, 29.54; H, 1.65; N; 7.65. 
Found: C, 29.59; H, 1.67; N, 7.69. 
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3.3. General Procedure for the Reaction of 2 and Aromatic Carbonyl Derivatives 4a–f, α-Carbonyl 
Ester 4g, Ketomalonate 4h, Acenaphtenedione 4i and Ketolactam 4j Using TDAE 
A solution of 2 (0.5,1.74 mmol) in anhydrous DMF (10 mL) and the corresponding carbonyl 
derivative 4a–j (5.22 mmol, 3 equivalents) were placed under nitrogen at −20 °C in a two-necked flask 
equipped with a silica-gel drying tube and a nitrogen inlet. The solution was stirred and maintained at 
this temperature for 30 min and then the TDAE (0.41 mL, 1.74 mmol, 1 equivalent) was added dropwise 
via a syringe. A red color immediately developed with the formation of a fine white precipitate. The 
solution was vigorously stirred at −20 °C for 1 h and then warmed to r.t. for 2 h. After this time TLC 
analysis (dichloromethane) clearly showed that 2 was totally consumed. The orange-red turbid solution 
was filtered (to remove the octamethyloxamidinium dibromide) and hydrolyzed with 80 mL of H2O. 
The aqueous solution was extracted with toluene (3 × 40 mL), the combined organic layers washed with 
H2O (3 × 40 mL) and dried over MgSO4. Evaporation of the solvent left an orange viscous liquid as 
crude product. Purification by silica gel chromatography and recrystallization in ethyl alcohol gave the 
corresponding products. 
5-(2-Hydroxy-2-(4-nitrophenyl)ethyl)-3-methyl-6-nitrobenzo[d]oxazol-2(3H)-one (5a): Brown solid; 
mp 233 °C; 1H-NMR (DMSO-d6): δ 3.37 (s, 3H, NCH3), 3.17–3.33 (m, 2H, 2 × CH), 4.92–5.01 (m, 1H, 
1H, CH), 5.67 (bs, 1H, OH), 7.33 (s, 1H, CH), 7.61 (d, J = 8,5 Hz, 2H, 2 × CH), 8.00 (s, 1H, CH), 8.21 
(d, J = 8.5 Hz, 2H, 2 × CH). 13C-NMR (DMSO-d6): δ 28.9 (NCH3), 42.2 (CH2), 72.1 (CH), 106.7 (CH), 
112.5 (CH), 123.6 (2 × CH), 127.0 (2 × CH), 131.2 (C), 135.8 (C), 140.2 (C), 144.1 (C), 146.7 (C), 153.2 
(C), 154.3 (CO). HRMS (EI): calcd for C16H13N3O7 (M+) 337.1092, found 337.1092. 
5-(2-(4-Bromophenyl)-2-hydroxyethyl)-3-methyl-6-nitrobenzo[d]oxazol-2(3H)-one (5b): Brown solid; 
mp 213 °C; 1H-NMR (CDCl3): δ 2.13 (d, J = 3.2 Hz, 1H, OH), 3.13 (dd, J = 13.7 Hz, J = 9.1 Hz, 1H, 
CH), 3.43 (s, 3H, NCH3), 3.50 (dd, J = 13.7 Hz, J = 3.7 Hz, 1H, CH), 5.06 (dd, J = 9.1 Hz, J = 3.7 Hz, 1H, 
CH), 6.85 (s, 1H, CH), 7.33 (d, J = 8.4 Hz, 2H, 2 × CH), 7.52 (d, J = 8.4 Hz, 2H, 2 × CH), 7.94 (s, 1H, 
CH). 13C-NMR (CDCl3): δ 28.6 (NCH3), 43.7 (CH2), 73.5 (CH), 107.5 (CH), 111.9 (CH), 121.7 (C), 
127.3 (2 × CH), 131.7 (2 × CH), 135.6 (C), 140.8 (C), 142.7 (CH), 144.0 (C), 154.3 (CO). C-NO2 was 
not observed under these experimental conditions. Anal. Calcld for C16H13BrN2O5 (393.19) C, 48.88; H, 
3.33; N; 7.12. Found: C, 48.91; H, 3.39; N, 7.19. 
4-(1-Hydroxy-2-(3-methyl-6-nitro-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)ethyl)benzonitrile (5c): 
Yellow solid; mp 213 °C; 1H-NMR (CDCl3): δ 2.27 (d, J = 3.0 Hz, 1H, OH), 3.05 (dd, J = 13.5 Hz,  
J = 9.4 Hz, 1H, CH), 3.46 (s, 3H, NCH3), 3.57 (dd, J = 13.5 Hz, J = 2.6 Hz, 1H, CH), 5,15 (dd, J = 9.4 Hz, 
J = 2.6 HZ, 1H, CH), 6.93 (s, 1H, CH), 7.61 (d, J = 8.3 Hz, 2H, 2 × CH), 7.70 (d, J = 8.3 Hz, 2H,  
2 × CH); 7.98 (s,1H, CH). 13C-NMR (CDCl3): δ 28.6 (NCH3), 43.8 (CH2), 73.3 (CH), 107.6 (CH), 111.7 
(C), 112.0 (CH), 118.7 (C), 126.3 (2 × CH), 131.5 (C), 132.5 (2 × CH), 135.7 (C), 140.9 (C), 149.0 (C), 
154.2 (CO). C-NO2 was not observed under these experimental conditions. HRMS (EI): calcd for 
C17H13N3O5 (M+) 357.1193, found 357.1194. 
5-(2-Hydroxy-2-(2-nitrophenyl)ethyl)-3-methyl-6-nitrobenzo[d]oxazol-2(3H)-one (5d): Brown solid; 
mp 130 °C; 1H-NMR (CDCl3): δ 3.36 (dd, J = 13.8 Hz, J = 8.8 Hz, 1H, CH), 3.41 (s, 3H, NCH3), 3.56 (dd, 
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J = 13.8 Hz, J = 3.2 Hz, 1H, CH), 5.47 (dd, J = 8.8 Hz, J = 3.2 Hz, 1H, CH), 7.05 (s, 1H, CH), 7.44 (t,  
J = 7.0 Hz, 1H, CH), 7.65 (t, J = 7.6 Hz, 1H, CH), 7.73 (s, 1H, CH), 7.80 (d, J = 7.0 Hz, 1H, CH), 7.89 (d, 
J = 7.6 Hz, 1H, CH). 13C-NMR (CDCl3): δ 28.5 (NCH3), 40.6 (CH2), 70.4 (CH), 107.1 (CH), 111.0 (CH), 
124.5 (CH), 128.4 (CH), 128.6 (CH), 131.1 (C), 133.9 (CH), 135.5 (C), 139.1 (C), 140.5 (C), 144.8 (C), 
147.4 (C), 154.3 (CO). HRMS (EI): calcd for C16H13N3O7 (M+) 337.1092, found 337.1092. 
5-(2-(2-Bromophenyl)-2-hydroxyethyl)-3-methyl-6-nitrobenzo[d]oxazol-2(3H)-one (5e): Yellow solid; 
mp 159 °C; 1H-NMR (DMSO-d6): δ 3.29 (s, 3H, NCH3), 3.30–3.33 (m, 2H, CH2), 5.51 (bs, 1H, CH), 
7.15 (s, 1H, CH), 7.21 (d, J = 7.3 Hz, 1H, CH), 7.40 (t, J = 7.7 Hz, 1H, CH), 7.51–7.54 (m, 2H,  
2 × CH), 7.95 (s, 1H, CH). 13C-NMR (DMSO-d6): δ 28.6 (NCH3), 40.5 (CH2), 71.35 (CH), 106.6 (CH), 
111.9 (CH), 121.4 (C), 128.1 (CH), 128.3 (CH), 129.3 (C), 130.5 (CH), 132.3 (CH), 135.4 (C), 140.1 (C), 
143.8 (C), 144.7 (C), 154.3 (CO). HRMS (EI): calcd for C16H13BrN2O5 (M+) 410.0346, found 410.0347. 
5-(2-(3-Bromophenyl)-2-hydroxyethyl)-3-methyl-6-nitrobenzo[d]oxazol-2(3H)-one (5f): Yellow solid; 
mp 154 °C; 1H-NMR (CDCl3): δ 2.15 (d, J = 2.9 Hz, 1H, OH), 3.13 (dd, J = 13.6 Hz, J = 9.0 Hz, 1H, 
CH), 3.44 (s, 3H, NCH3), 3.53 (dd, J = 13.6 Hz, J = 3.4 Hz, 1H, CH), 5.08 (dd, J = 9.0 Hz, J = 3.4 Hz, 
1H, CH), 6.87 (s, 1H, CH), 7.29 (s, 1H, CH), 7.35–7.48 (m, 2H, 2 × CH), 7.61–7.63 (m, 1H, CH), 7.95 
(s,1H, CH). 13C-NMR (CDCl3): δ 28.5 (NCH3), 43.7 (CH2), 73.4 (CH), 107.5 (CH), 111.9 (CH), 122.8 
(C), 124.3 (CH), 128.7 (CH), 130.2 (CH), 131.0 (CH), 131.7 (C), 135.6 (C), 140.8 (C), 144.0 (C), 146.1 
(C), 154.3 (CO). Anal. Calcld for C16H13BrN2O5 (393.19) C, 48.88; H, 3.33; N, 7.12. Found: C, 49.11; 
H, 3.46; N, 7.28. 
Ethyl 2-hydroxy-3-(3-methyl-6-nitro-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)propanoate (5g): Yellow solid; 
mp 136 °C; 1H-NMR (CDCl3): δ 1.32 (t, J = 7.1 Hz, 3H, CH3), 2.99 (d, J = 5.3 Hz, 1H, OH), 3.17 (dd, 
J = 13.9 Hz, J = 8.8 Hz, 1H, CH), 3.46 (s, 3H, NCH3), 3.68 (dd, J = 13.9 Hz, J = 3.7 Hz, 1H, CH), 4.28 
(q, J = 7.1 Hz 2H, CH2), 4.50–4.55 (m, 1H, CH), 7.02 (s, 1H, CH), 7.91 (s, 1H, CH). 13C-NMR (CDCl3): 
δ 14.1 (CH3), 28.6 (NCH3), 37.9 (CH2), 62.4 (CH2), 70.1 (CH), 107.4 (CH), 111.6 (CH), 130.3 (CH), 
135.5 (CH), 140.8 (CH), 144.2 (CH), 154.2 (CO), 173.9 (CO). Anal. Calcld for C13H14N2O7 (310.26) C, 
50.33; H, 4.55; N, 9.03. Found: C, 50.28; H, 4.54; N, 8.91 
Diethyl 2-hydroxy-2-((3-methyl-6-nitro-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)methyl)malonate (5h): 
Yellow solid; mp 111 °C; 1H-NMR (CDCl3): δ 1.27 (t, J = 7.1 Hz, 6H, 2xCH3), 3.43 (s, 3H, NCH3), 
3.85 (bs, 1H, OH), 3.88 (s, 2H, CH2), 4.11–4.34 (m, 4H, CH2), 7.14 (s, 1H, CH), 7.75 (s, 1H, CH).  
13C-NMR (CDCl3): δ 13.9 (2 × CH3), 28.5 (NCH3), 35.5 (2 × CH2), 63.1 (CH2), 78.4 (C-OH), 107.2 
(CH), 111.8 (CH), 127.1 (C), 134.8 (C), 140.8 (C), 145.6 (C), 154.2 (CO), 169.4 (2 × CO). Anal. Calcld 
for C16H18N2O9 (382.32) C, 50.26, H, 4.75, N, 7.33. Found: C, 50.25, H, 4.83, N, 7.18. 
5-((1-Hydroxy-2-oxo-1,2-dihydroacenaphthylen-1-yl)methyl)-3-methyl-6-nitrobenzo[d]oxazol-2(3H)-one 
(5i): Green solid; mp 204 °C; 1H-NMR (CDCl3): δ 3.45 (s, 3H, NCH3), 3.64 (d, J = 14.0 Hz, 1H, CH), 
3.84 (d, J = 14.0 Hz, 1H, CH), 7.12 (s, 1H, CH), 7.27 (d, J = 7.3 Hz, 1H, CH), 7.61 (dd, J = 8.0 Hz,  
J = 7.3 Hz,1H, CH), 7.77 (dd, J = 7.8 Hz, J = 7.3 Hz, 1H, CH), 7.88 (s, 1H, CH), 7.89–7.98 (m, 2H,  
2 × CH), 8.15 (d, J = 8.0 Hz, 1H, CH). 13C-NMR (CDCl3): δ 28.6 (NCH3), 40.9 (CH2), 79.8 (C-OH), 
107.5 (CH), 112.4 (CH), 120.3 (CH), 122.7 (CH), 125.9 (CH), 128.6 (CH), 128.7 (CH+C), 130.1 (C), 
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130.7 (C), 132.4 (CH), 135.3 (C), 138.7 (C), 140.7 (C), 141.0 (C), 144.5 (C), 154.3 (CO); 203.8 (CO). 
Anal. Calcld for C21H14N2O6 (390.35) C, 64.62, H, 3.62, N, 7.18. Found: C, 64.15, H, 3.72, N, 7.05. 
5-((3-Hydroxy-1-methyl-2-oxoindolin-3-yl)methyl)-3-methyl-6-nitrobenzo[d]oxazol-2(3H)-one (5j): 
Yellow solid; mp 253 °C; 1H-NMR (DMSO-d6): δ 3.03 (s, 3H, NCH3), 3.31 (s, 3H, NCH3), 3.36 (d,  
J = 13.7 Hz, 1H, CH), 3.66 (d, J = 13.7 Hz, 1H, CH), 6.19 (s, 1H, CH), 6.78 (d, J = 6.8 Hz, 1H, CH),  
6.91–6.95 (m, 2H, 2 × CH), 7.13 (s, 1H, CH), 7.24–7.31 (m, 1H, CH). 13C-NMR (DMSO-d6): δ 26.0 
(NCH3); 28.5 (NCH3), 75.4 (C-OH), 106.7 (CH), 108.6 (CH), 112.9 (CH), 122.3 (CH), 123.9 (CH), 
127.6 (C), 129.4 (CH), 130.5 (C), 135.0 (C), 140.3 (C), 142.8 (C), 144.7 (C), 154.3 (CO), 176.8 (CO).  
C-NO2 was not observed under these experimental conditions. Anal. Calcld for C18H15N3O6 (369.33) C, 
58.54, H, 4.09, N, 11.38. Found: C, 58.26, H, 4.25, N, 11.01. 
1-(3-Methyl-6-nitro-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)-2-(4-nitrophenyl)ethyl 4-nitrobenzoate (6): 
Yellow solid; mp 305 °C; 1H-NMR (CDCl3): δ 3.35 (s, 3H, NCH3), 3.73 (d, J = 6.2 Hz, 2H, CH2), 6.44 
(t, J = 6.2 Hz, 1H, CH), 6.84 (s, 1H, CH), 7.68 (d, J = 8.5 Hz, 2H, 2 × CH), 7.97 (s, 1H, CH), 8.17 (d,  
J = 8.8 Hz, 2H, 2 × CH), 8.28 (d, J = 8.5 Hz, 1H, 2 × CH), 8.32 (d, J = 8.5 Hz, 1H, 2 × CH). 13C-NMR 
(CDCl3): δ 28.5 (NCH3), 40.8 (CH2), 76.4 (CH), 108.1 (CH), 110.7 (CH), 114.1 (C), 123.8 (2 × CH), 
124.3 (2 × CH), 127.1 (2 × CH), 129.6 (C), 130.7 (2 × CH), 134.4 (C), 135.9 (C), 141.2 (C), 145.9 (C), 
148.1 (C), 150.9 (C), 153.8 (CO). HRMS (EI): calcd for C23H16N4O10 (M+) 526.1205, found 526.1209. 
3.4. General Procedure for the Reaction of 3 and Aromatic Carbonyl Derivatives 4a–f, α-Carbonyl 
Ester 4g, Ketomalonate 4h, Acenaphtenedione 4i and Keto-lactam 4j Using TDAE 
A solution of 3 (0.5 g, 1.36 mmol) in anhydrous DMF (10 mL) and the corresponding carbonyl 
derivative 4a–j (4.098 mmol, 3 equivalents) were placed under nitrogen at −20 °C in a two-necked flask 
equipped with a silica-gel drying tube and a nitrogen inlet. The solution was stirred and maintained at 
this temperature for 30 min and then the TDAE (0.48 mL, 2.049 mmol, 1.5 equivalent) was added 
dropwise via a syringe. A red color immediately developed with the formation of a fine white precipitate. 
The solution was vigorously stirred at −20 °C for 1 h and then warmed to rt for 2 h. After this time TLC 
analysis (dichloromethane) clearly showed that 3 was totally consumed. The orange-red turbid solution 
was filtered (to remove the octamethyloxamidinium dibromide) and hydrolyzed with 80 mL of H2O. 
The aqueous solution was extracted with toluene (3 × 40 mL), the combined organic layers washed with 
H2O (3 × 40 mL) and dried over MgSO4. Evaporation of the solvent left an orange viscous liquid as 
crude product. Purification by silica gel chromatography and recrystallization in ethyl alcohol solvent 
gave the corresponding oxiranes 7a–j. 
3-Methyl-6-nitro-5-(3-(4-nitrophenyl)oxiran-2-yl)benzo[d]oxazol-2(3H)-one (7a) trans-isomer: Yellow 
solid; mp 224 °C; 1H-NMR (CDCl3): δ 3.52 (s, 3H, NCH3), 3.92 (d, J = 1.9 Hz, 1H, CH), 4.54 (d,  
J = 1.9 Hz, 1H, CH), 7.33 (s, H, CH), 7.60 (d, J = 8.7 Hz, 2H, 2 × CH), 8.13 (s, 1H, CH), 8.30 (d,  
J = 8.7 Hz, 2H, 2 × CH). 13C-NMR (CDCl3): δ 28.8 (NCH3), 61.0 (CH), 61.1 (CH), 105.7 (CH), 107.4 
(CH), 124.0 (2 × CH), 126.6 (2 × CH), 131.8 (C), 137.28 (C), 141.6 (C), 142.1 (C), 143.0 (C), 148.2 
(CO). C-NO2 was not observed under these experimental conditions. HRMS (EI): calcd for C16H11N3O7 
(M+) 375.0935, found 375.0943. 
Molecules 2015, 20 1271 
 
 
5-(3-(4-Bromophenyl)oxiran-2-yl)-3-methyl-6-nitrobenzo[d]oxazol-2(3H)-one (7b) trans-isomer: 
Yellow solid; mp 209 °C; 1H-NMR (CDCl3): δ 3.51 (s, 3H, NCH3), 3.77 (d, J = 1.9 Hz, 1H, CH), 3.54 
(d, J = 1.9 Hz, 1H, CH), 7.28 (d, J = 8.4 Hz, 2H, 2 × CH), 7.31 (s, 1H, CH), 7.54 (d, J = 8.4 Hz, 2H, 2 × CH), 
8.11 (s, 1H, CH). 13C-NMR (CDCl3): δ 28.7 (NCH3), 60.5 (CH), 61.7 (CH), 105.6 (CH), 107.3 (CH), 
122.8 (C), 127.5 (2 × CH), 131.9 (2 × CH), 132.5 (C), 134.8 (C), 137.0 (C), 141.3 (C), 154.1 (CO). Anal. 
Calcld for C16H11BrN2O5 (391.17) C, 49.13; H, 2.83; N, 7.16. Found: C, 49.27; H, 2.92; N, 7.85. 
4-(3-(3-Methyl-6-nitro-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)oxiran-2-yl)benzonitrile (7c) trans-isomer: 
Yellow solid; mp 213 °C; 1H-NMR (CDCl3): δ 3.51 (s, 3H, NCH3), 3.86 (d, J = 1.8 Hz, H, CH), 4.52 (d, 
J = 1.8 Hz, H, CH), 7.32 (s, 1H, CH), 7.53 (d, J = 8.3 Hz, 2H, 2 × CH), 7.72 (d, J = 8.3 Hz, 2H, 2 × CH), 
8.12 (s, 1H, CH). 13C-NMR (CDCl3): δ 28.7(NCH3), 61.0 (CH), 61.2 (CH), 105.7 (CH), 107.3 (CH), 
112.6 (C), 118.5 (C), 126.5 (2 × CH), 131.9 (C), 132.5 (2 × CH), 137.1(C), 141.1 (C), 141.5 (C), 
142.1(C); 154.1 (CO). HRMS (EI): calcd for C17H11N3O5 (M+) 355.1037, found 355.1036. 
3-Methyl-6-nitro-5-(3-(2-nitrophenyl)oxiran-2-yl)benzo[d]oxazol-2(3H)-one (7d) trans-isomer: yellow 
solid; mp 215 °C; 1H-NMR (CDCl3): δ 3.52 (s, 3H, NCH3), 4.54 (d, J = 2.0 Hz, 1H, CH), 4.60 (d,  
J = 2.0 Hz, 1H, CH), 7.36 (s, 1H, CH), 7.52–7.61 (m, 1H, CH), 7.75–7.77 (m, 2H, 2 × CH), 8.14 (s, 1H, 
CH), 8.23 (d, J = 8.0 Hz, 1H, CH). 13C-NMR (CDCl3): δ 28.7 (NCH3), 59.9 (CH), 60.0 (CH), 105.5 (CH), 
107.6 (CH), 125.2 (CH), 126.9 (CH), 129.2 (C), 131.8 (CH), 132.5 (C), 134.4 (CH), 137.0 (C), 141.5 (C), 
142.6 (C), 147.9 (C), 154.2 (CO). HRMS (EI): calcd for C16H11N3O7 (M+) 375.0935, found 375.0940. 
3-Methyl-6-nitro-5-(3-(2-nitrophenyl)oxiran-2-yl)benzo[d]oxazol-2(3H)-one (7d) cis-isomer: Beige solid; 
mp 166 °C; 1H-NMR (CDCl3): δ 3.38 (s, 3H, NCH3), 5.14 (d, J = 4.9 Hz, 1H, CH), 5.17 (d, J = 4.9 Hz, 
1H, CH), 7.03 (s, 1H, CH), 7.30–7.40 (m, 1H, CH), 7.44–7.46 (m, 2H, 2 × CH), 7.86–7.90 (m, 2H,  
2 × CH). 13C-NMR (CDCl3): δ 28.6 (NCH3), 59.0 (2 × CH), 107.3 (CH), 107.4 (CH), 124.7 (CH), 128.8 
(CH), 128.9 (C), 129.2 (CH), 129.4 (C), 132.7 (CH), 135.9 (C), 141.2 (C), 148.5 (C), 153.9 (CO). Anal. 
Calcld for C16H11N3O7 (357.27) C, 53.79; H, 3.10; N, 11.76. Found: C, 53.48; H, 3.30; N, 11.44. 
5-(3-(2-Bromophenyl)oxiran-2-yl)-3-methyl-6-nitrobenzo[d]oxazol-2(3H)-one (7e) trans-isomer: 
Green solid; mp 203 °C; 1H-NMR (CDCl3): δ 3.52 (s, 3H, NCH3), 4.09 (d, J = 1.9 Hz, 1H, CH), 4.57 (d,  
J = 1.9 Hz, 1H, CH), 7.20–7.29 (m, 1H, CH), 7.36 (s, 1H, CH), 7.38–7.47 (m, 2H, 2 × CH), 7.60 (d,  
J = 7.5 Hz, 1H, CH), 8.12 (s, 1H, CH). 13C-NMR (CDCl3): δ 28.7 (NCH3), 60.1 (CH), 62.0 (CH), 105.6 
(CH), 107.4 (CH), 123.1 (C), 126.1 (CH), 127.8 (CH), 130.0 (CH), 132.2 (C), 132.7 (CH), 135.2 (C), 137.0 
(C), 141.4 (C), 142.4 (C), 154.2 (CO). Anal. Calcld for C16H11BrN2O5 (391.17) C, 49.13; H, 2.83; N, 
7.16. Found: C, 49.27; H, 2.93; N, 7.17. 
5-(3-(2-Bromophenyl)oxiran-2-yl)-3-methyl-6-nitrobenzo[d]oxazol-2(3H)-one (7e) cis-isomer: Green solid; 
mp 151 °C; 1H-NMR (CDCl3): δ 3.42 (s, 3H, NCH3), 4.71 (d, J = 4.4 Hz, 1H, CH), 5.17 (d,  
J = 4.4 Hz, 1H, CH), 6.98–7.14 (m, 3H, 3 × CH), 7.16 (s, 1H, CH), 7.36–7.42 (m, 1H, CH), 7.93 (s, 1H, 
CH). 13C-NMR (CDCl3): δ 28.6 (NCH3), 59.3 (CH), 61.0 (CH), 107.3 (CH), 107.9 (CH), 122.5 (C), 126.4 
(CH), 128.0 (CH), 129.4 (C), 129.6 (CH), 132.7 (CH), 132.9 (C), 135.8 (C), 141.1 (C), 142.5 (C), 154.0 
(CO). Anal. Calcld for C16H11BrN2O5 (391.17) C, 49.13; H, 2.83; N, 7.16. Found: C, 49.42; H, 3.02; N, 7.28. 
Molecules 2015, 20 1272 
 
 
5-(3-(3-Bromophenyl)oxiran-2-yl)-3-methyl-6-nitrobenzo[d]oxazol-2(3H)-one (7f) trans-isomer: Beige 
solid; mp 165 °C; 1H-NMR (CDCl3): δ 3.51 (s, 3H, 3H, NCH3), 3.77 (d, J = 1.9 Hz, 1H, CH), 4.55 (d,  
J = 1.9 Hz, 1H, CH), 7.24–7.28 (m, 1H, CH), 7.32 (s, 1H, CH), 7.33–7.38 (m, 1H, CH), 7.49–7.54 (m, 
2H, 2 × CH), 8.11 (s, 1H, CH). 13C-NMR (CDCl3): δ 28.7 (NCH3), 60.6 (CH), 61.4 (CH), 105.7 (CH), 
107.3 (CH), 122.8 (C), 124.6 (CH), 128.7 (CH), 130.2 (CH), 131.9 (CH), 132.3 (C), 137.0 (C), 138.1 
(C), 141.4 (C), 142.1 (C), 154.1 (CO). Anal. Calcld for C16H11BrN2O5 (391.17) C, 49.13; H, 2.83; N, 
7.16. Found: C, 49.30; H, 2.97; N, 7.10. 
Ethyl 3-(3-methyl-6-nitro-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)oxirane-2-carboxylate (7g) trans-isomer: 
Light yellow needles; mp 199 °C; 1H-NMR (CDCl3): δ 1.36 (t, J = 7.2 Hz, H, CH); 3.38 (d, J = 1.9 Hz, 
3H, CH); 3.48 (s, 3H, NCH3); 4,35 (q, J = 7.2 Hz, 2H, CH2); 4,75 (d, J = 1.9 Hz, 1H, CH); 7.19 (s, 1H, 
CH); 8.12 (s, 1H, CH). 13C-NMR (CDCl3): δ 14.1 (CH3), 28.8 (NCH3), 56.0 (CH), 56.6 (CH), 62.2 
(CH2), 105.8 (CH), 107.4 (CH), 130.9 (C), 137.0 (C), 141.6 (C), 142.2 (C), 154.0 (CO), 167.2 (CO). 
HRMS (EI): calcd for C13H12N2O7 (M+) 309.0717, found 309.0713. 
Diethyl 3-(3-methyl-6-nitro-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)oxirane-2,2-dicarboxylate (7h) 
trans-isomer: Dark brown; mp 118 °C; 1H-NMR (CDCl3): δ 0.98 (t, J = 7.2 Hz, 3H, CH3), 1.37 (t,  
J = 7.2 Hz, 3H, CH3), 3.48 (s, 3H, NCH3), 3.98 (q, J = 7.2 Hz, 2H, CH2), 4.39 (q, J = 7.2 Hz, 2H, CH2), 
5.14 (s, 1H, CH), 7.24 (s, 1H, CH), 8.12 (s, 1H, CH). 13C-NMR (CDCl3): δ 13.8 (CH3), 14.0 (CH3), 28.9 
(NCH3), 61.2 (CH), 62.2 (CH2), 63.3 (CH2), 107.2 (CH), 107.4 (CH), 127.9 (C), 136.7 (C), 141.9 (C), 142.3 
(C), 153.9 (C), 163.3 (CO), 164.6 (CO). Anal. Calcld for C16H16N2O9 (380.31) C, 50.53; H, 4.24; N, 
7.37. Found: C, 50.96; H, 4.54; N, 7.25. 
3-Methyl-6-nitro-5-(2-oxo-2H-spiro[acenaphthylene-1,2'-oxiran]-3'-yl)benzo[d]oxazol-2(3H)-one (7i) 
like-isomer: Yellow solid; mp 235 °C; 1H-NMR (CDCl3): δ 3.59 (s, 3H, NCH3), 5.29 (s, 1H, CH), 7.62 
(d, J = 6.8 Hz, 1H, CH2), 7.74 (s, 2H, 2 × CH); 7.77–7.80 (m, 1H, CH), 7.85 (d, J = 6.7 Hz, 1H, CH2), 
8.01 (d, J = 8.4 Hz, 1H, CH2), 8.06 (s, 1H, CH), 8.19 (d, J = 8.1 Hz, 1H, CH). 13C-NMR (CDCl3): δ 28.9 
(NCH3), 65.8 (CH), 67.1 (C), 106.8 (CH), 108.9 (CH), 118.9 (CH), 122.1 (CH), 126.5 (CH), 128.3 (CH), 
128.7 (CH), 129.2 (C), 130.4 (C), 131.2 (C), 132.1 (C), 132.3 (CH), 136.5 (C), 141.4 (C), 141.7 (C), 
142.5 (C), 154.2 (CO), 196.0 (CO). Anal. Calcld for C21H12N2O6 (388.33) C, 64.95; H, 3.11; N, 7.21. 
Found: C, 64.08; H, 3.26; N, 6.85. 
3-Methyl-6-nitro-5-(2-oxo-2H-spiro[acenaphthylene-1,2'-oxiran]-3'-yl)benzo[d]oxazol-2(3H)-one (7i) 
unlike-isomer: Beige solid; mp 201 °C; 1H-NMR (CDCl3): δ 3.63 (s, 3H, NCH3), 5.30 (s, 1H, CH), 6.34 
(d, J = 6.8 Hz, 1H, CH2), 7.32 (d, J = 6,7 Hz, 1H, CH), 7.67 (s, 1H, CH), 7.77–7.88 (m, 2H, 2 × CH), 
8.07 (s, 1H, CH), 8.12 (d, J = 1.7 Hz,1H, CH), CH), 8.16 (d, J = 3.2 Hz,1H, CH). 13C-NMR (CDCl3): δ 
29.0 (NCH3), 64.7 (CH), 66.5 (C); 107.3 (CH), 107.7 (CH), 119.1 (CH), 122.7 (CH), 126.8 (CH), 127.8 
(CH), 128.5 (CH), 129.7 (C), 130.2 (C), 130.5 (C), 130.6 (C), 132.3 (CH), 136.9 (C), 141.9 (C), 143.2 
(C), 154.0 (C), 196.3 (CO). C-NO2 was not observed under these experimental conditions. HRMS (EI): 
calcd for C21H12N2O6 (M+) 389.0768, found 389.0768. 
1-Methyl-3'-(3-methyl-6-nitro-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)spiro[indoline-3,2'-oxiran]-2-one 
(7j) like-isomer: Beige solid; mp 190 °C; 1H-NMR (CDCl3): δ 3.13 (s, 3H, NCH3), 3.54 (s, 3H, NCH3), 
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5.15 (s, 1H, CH), 6.93 (dd, J = 7.8 Hz, J = 0.7 Hz,1H, CH), 7.17 (td, J = 7.5 Hz, J = 0.7 Hz,1H, CH), 
7.32 (dd, J = 7.3 Hz, J = 0.7 Hz, 1H, CH), 7.44 (td, J = 7.3 Hz, J = 1.4 Hz, 1H, CH), 7.62 (s, 1H, CH), 
8.08 (s, 1H, CH). 13C-NMR (CDCl3): δ 26.5 (NCH3), 28.8(NCH3), 62.7 (CH), 65.0 (C), 106.8 (CH), 
108.9 (CH), 109.0 (CH), 122.2 (CH), 122.3 (C), 123.2 (CH), 128.8 (C), 130.8 (CH), 136.4 (C), 141.5 
(C), 141.7 (C), 144.8 (CH), 154.2 (CO), 169.6 (CO). Anal. Calcld for C18H13N3O6 (367.31) C, 58.86; H, 
3.57; N, 11.44. Found: C, 58.85; H, 3.71; N, 11.31. 
1-Methyl-3'-(3-methyl-6-nitro-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)spiro[indoline-3,2'-oxiran]-2-one 
(7j) unlike-isomer: Beige solid; mp 211 °C; 1H-NMR (CDCl3): δ 3.33 (s, 3H, NCH3), 3.59 (s, 3H, NCH3), 
5.18 (s, 1H, CH), 6.01 (d, J = 7.5 Hz, 1H, CH), 6.71 (t, J = 7.5 Hz, 1H, CH), 6.88 (d, J = 7.7 Hz, 1H, 
CH), 7.32 (d, J = 7.7 Hz, 1H, CH), 7.57 (s, 1H, CH), 8.08 (s, 1H, CH). 13C-NMR (CDCl3): δ 26.8 
(NCH3), 29.0 (NCH3), 62.2 (CH), 64.4 (C), 107.3 (CH), 107.8 (CH), 109.2 (CH), 119.8 (C), 122.0 (CH), 
122.4 (CH), 129.4 (C), 130.9 (CH), 137.0 (C), 141.8 (C), 141.9 (C), 145.6 (C), 154.0 (CO), 170.6 (CO). 
HRMS (EI): calcd for C18H13N3O6 (M+) 368.0877, found 368.0876. 
4. Conclusions 
In conclusion, we have investigated the reactivity of some new benzoxazolone derivatives formed via 
the TDAE strategy. This is the first example of the use of the TDAE strategy to generate a benzoxazolinonic 
anion, which cannot be formed via the standard organometallic strategy. This study brought to light a 
new and original reactivity and we have defined some limitations of the TDAE strategy. We show that 
5-(bromomethyl)-3-methyl-6-nitrobenzo[d]oxazol-2(3H)-one (2), in addition to providing the expected 
alcohols 5a–i in moderate to good yields, furnished an unexpected ester 6 formed in 23% yield, particularly 
with the p-nitrobenzaldehyde. The reactions of 5-(dibromomethyl)-3-methyl-6-nitro-benzo[d]oxazol-
2(3H)-one (3) led to the expected oxiranes 7a–j and mixtures of original stereoisomers 7i–j in good 
yields. All these synthesized products are currently undergoing pharmacological evaluation. 
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